Biological and chemical terrorism

Journal of Pediatrics

Volumn 141, Issue 3, 2002, Pages 311-326

  Henretig, Fred M ^a,b,c   Cieslak, Theodore J ^a,b,c   Eitzen Jr , Edward M ^a,b,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b San Antonio Military Pediat Center   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; CHEMICAL WARFARE AGENT; CHLORINE; CYANIDE; LEWISITE; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; MUSTARD GAS DERIVATIVE; PHOSGENE; SARIN; SOMAN; TABUN;

BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; BOTULISM; CHEMICAL WARFARE; HEMORRHAGIC FEVER; PLAGUE; PRIORITY JOURNAL; REVIEW; SMALLPOX; TERRORISM; VICTIM;

EID: 0036734223     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2002.127408     Document Type: Article

References (66)

1. Chemical and biological terrorism and its impact on children: A subject review
2. The emergency department response to incidents of biological and chemical terrorism
3. Education is the key to defense against bioterrorism
4. Biological and chemical terrorism defense: A view from the "front lines" of public health
5. Biological warfare: A historical perspective
6. Biological and chemical terrorism: Strategic plan for preparedness and response
7. A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars
8. Report on 640 victims of the Tokyo subway sarin attack
9. Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax
10. Chemical warfare agents: Emergency medical and emergency public health issues
11. Clinical recognition and management of patients exposed to biological warfare agents
12. Medical management of vulnerable populations and co-morbid conditions of victims of bioterrorism
13. Ability of hospitals to care for pediatric emergency patients
14. Bioterrorism: Agents of concern
15. Anthrax as a biological weapon: Medical and public health management
16. Smallpox as a biological weapon: Medical and public health management
17. Plague as a biological weapon: Medical and public health management
18. Botulinum toxin as a biological weapon: Medical and public health management
19. Tularemia as a biological weapon: Medical and public health management
20. Anthrax as a biological weapon, 2002: Updated recommendations for management
21. Fluoroquinolones, tetracyclines
22. Use of fluroquinolones for empirical management of febrile neutropenia in pediatric cancer patients
23. Oral ciprofloxacin in the treatment of pseudomonas exacerbations of pediatric cystic fibrosis: Clinical efficacy and safety evaluation using magnetic resonance image scanning
24. Doxycycline and staining of permanent teeth
25. Investigation of bioterrorism-related anthrax: Connecticut, 2001
26. Update: Investigaion of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis
27. The Sverdlovsk anthrax outbreak of 1979
28. Fatal inhalational anthrax in a 94-year-old Connecticut woman
29. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States
30. Cutaneous anthrax associated with microangiopathic hemolytic anemia and coagulopathy in a 7-month-old infant
31. Cutaneous anthrax infection
32. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy
33. Notice to readers: Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax
34. The bioweaponeers
35. Diagnosis and treatment of smallpox
36. Smallpox in tripolitania, 1946: An epidemiological and clinical study of 500 cases, including trials of penicillin treatment
37. Eczema vaccinatum: A timely reminder
38. Clinical responses to undiluted and diluted smallpox vaccine
39. Dose-related effects of smallpox vaccine
40. Experience with the use of an investigational F(ab′) heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt
41. Clinical trial of human botulism immune globulin
42. Weapons of mass destruction events with contaminated casualties: Effective planning for health care facilities
43. Chemical warfare agents: II. Nerve agents
44. Nerve agents
45. Chemical warfare: Nerve agent poisoning
46. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology
47. Carbamate and organophosphate poisoning in early childhood
48. Carbamate poisoning and oxime treatment in children: A clinical and laboratory study
49. The pharmacokinetics of continuous infusion pralidoxime in children with organophosphate poisoning
50. Atropine poisoning in children during the Persian Gulf crisis: A national survey in Israel
51. Amplification of the effectiveness of acetylcholinesterase for detoxification of organophosphorus compounds by bis-quaternary oximes
52. Effects of sarin on the nervous system in rescue team staff members and police officers 3 years after the Tokyo subway sarin attack
53. Skin manifestations of mustard gas in a group of 14 children and teenagers: A clinical study
54. Exposure to liquid sulfur mustard
55. Treament of acute chlorine gas inhalation with nebulized sodium bicarbonate
56. Nebulized sodium bicarbonate in acute chlorine inhalation
57. Protective effects of N-acetylcysteine treatment after phosgene exposure in rabbits
58. Efficacy of ibuprofen and pentoxifylline in the treatment of phosgene-induced acute lung injury
59. The treatment of cyanide poisoning in children
60. Cyanide poisoning: Pathophysiology and treatment recommendations
61. Hydroxocobalamin: Improved public health readiness for cyanide disasters
62. Pepper-spray-induced respiratory failure treated with extracorporeal membrane oxygenation
63. Medical management of the suspected victim of bioterrorism: An algorithmic approach to the undifferentiated patient
64. Bioterrorism and pediatric emergency medicine